MA45149A - Méthodes de traitement de la maladie d'alzheimer - Google Patents
Méthodes de traitement de la maladie d'alzheimerInfo
- Publication number
- MA45149A MA45149A MA045149A MA45149A MA45149A MA 45149 A MA45149 A MA 45149A MA 045149 A MA045149 A MA 045149A MA 45149 A MA45149 A MA 45149A MA 45149 A MA45149 A MA 45149A
- Authority
- MA
- Morocco
- Prior art keywords
- alzheimer
- disease
- treatment
- methods
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346818P | 2016-06-07 | 2016-06-07 | |
| US201662435531P | 2016-12-16 | 2016-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45149A true MA45149A (fr) | 2019-04-10 |
Family
ID=59067640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045149A MA45149A (fr) | 2016-06-07 | 2017-06-06 | Méthodes de traitement de la maladie d'alzheimer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200308259A1 (fr) |
| EP (1) | EP3464350A1 (fr) |
| JP (2) | JP2019517540A (fr) |
| KR (2) | KR20230165883A (fr) |
| CN (3) | CN109476730A (fr) |
| AU (1) | AU2017276656A1 (fr) |
| BR (1) | BR112018075300A2 (fr) |
| CA (1) | CA3026598A1 (fr) |
| IL (1) | IL263433B2 (fr) |
| MA (1) | MA45149A (fr) |
| MX (1) | MX2018015022A (fr) |
| WO (1) | WO2017211827A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| EP3696192A1 (fr) | 2019-02-15 | 2020-08-19 | Consejo Superior De Investigaciones Científicas | Cible thérapeutique et anticorps monoclonaux contre elle pour le diagnostic et le traitement de la maladie d'alzheimer |
| CR20210492A (es) | 2019-03-26 | 2021-11-19 | Janssen Pharmaceutica Nv | ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS |
| CN110511276A (zh) * | 2019-08-13 | 2019-11-29 | 王跃驹 | 植物作为宿主在表达Aducanumab抗体中的应用 |
| JP2022553329A (ja) * | 2019-10-22 | 2022-12-22 | バイオジェン・エムエイ・インコーポレイテッド | アルツハイマー病を治療するための抗ベータ－アミロイド抗体 |
| BR112023001061A2 (pt) | 2020-07-23 | 2023-04-04 | Othair Prothena Ltd | Anticorpos antiabeta |
| KR102321601B1 (ko) * | 2020-11-19 | 2021-11-05 | 주식회사 휴런 | 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법 |
| US20240270830A1 (en) * | 2021-06-07 | 2024-08-15 | Biogen Ma Inc. | Methods for treating alzheimer's disease |
| WO2023055733A1 (fr) * | 2021-09-30 | 2023-04-06 | The Scripps Research Institute | Composés pour réduire la neuro-inflammation |
| MX2024005999A (es) * | 2021-11-19 | 2024-05-30 | Ap Biosciences Inc | Anticuerpos bispecificos dirigidos a cd137 y usos de los mismos para la inmunoterapia anticancer. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201815827A (zh) * | 2006-07-14 | 2018-05-01 | 瑞士商Ａｃ免疫公司 | 抗β-類澱粉抗體或其抗原結合片段、其用途及使用方法 |
| PT2099826E (pt) * | 2007-01-05 | 2014-01-09 | Univ Zuerich | Anticorpo anti-beta-amilóide e suas utilizações |
| EP2627672B1 (fr) | 2010-10-11 | 2018-08-01 | Biogen Idec International Neuroscience GmbH | Anticorps anti-tau humain |
| RU2689674C2 (ru) * | 2012-10-15 | 2019-05-28 | Медиммьюн Лимитед | Антитела к бета-амилоиду |
| JP2016501247A (ja) * | 2012-12-07 | 2016-01-18 | バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー | 抗Ａβ抗体を使用して脳アミロイド斑を減少させる方法 |
| LT2935326T (lt) | 2012-12-21 | 2020-12-10 | Biogen Ma Inc. | Žmogaus antikūnai prieš tau baltymą |
| AU2015214058B2 (en) * | 2014-02-08 | 2020-07-09 | Genentech, Inc. | Methods of treating Alzheimer's Disease |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
-
2017
- 2017-06-06 IL IL263433A patent/IL263433B2/en unknown
- 2017-06-06 CN CN201780044190.9A patent/CN109476730A/zh active Pending
- 2017-06-06 KR KR1020237040938A patent/KR20230165883A/ko active Application Filing
- 2017-06-06 CN CN202210397435.9A patent/CN114931635A/zh active Pending
- 2017-06-06 JP JP2018563815A patent/JP2019517540A/ja not_active Withdrawn
- 2017-06-06 US US16/307,364 patent/US20200308259A1/en not_active Abandoned
- 2017-06-06 EP EP17730427.6A patent/EP3464350A1/fr active Pending
- 2017-06-06 CN CN202210397569.0A patent/CN114796481A/zh active Pending
- 2017-06-06 CA CA3026598A patent/CA3026598A1/fr active Pending
- 2017-06-06 BR BR112018075300-9A patent/BR112018075300A2/pt unknown
- 2017-06-06 WO PCT/EP2017/063711 patent/WO2017211827A1/fr active Application Filing
- 2017-06-06 KR KR1020197000443A patent/KR20190021311A/ko active Application Filing
- 2017-06-06 MA MA045149A patent/MA45149A/fr unknown
- 2017-06-06 AU AU2017276656A patent/AU2017276656A1/en not_active Abandoned
- 2017-06-06 MX MX2018015022A patent/MX2018015022A/es unknown
-
2022
- 2022-02-25 US US17/681,011 patent/US20220281963A1/en active Pending
- 2022-08-15 JP JP2022129326A patent/JP2022145965A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL263433A (en) | 2019-01-31 |
| CA3026598A1 (fr) | 2017-12-14 |
| CN109476730A (zh) | 2019-03-15 |
| KR20190021311A (ko) | 2019-03-05 |
| AU2017276656A1 (en) | 2018-12-13 |
| US20200308259A1 (en) | 2020-10-01 |
| CN114931635A (zh) | 2022-08-23 |
| CN114796481A (zh) | 2022-07-29 |
| KR20230165883A (ko) | 2023-12-05 |
| IL263433B2 (en) | 2024-03-01 |
| IL263433B1 (en) | 2023-11-01 |
| JP2019517540A (ja) | 2019-06-24 |
| JP2022145965A (ja) | 2022-10-04 |
| BR112018075300A2 (pt) | 2019-04-30 |
| US20220281963A1 (en) | 2022-09-08 |
| MX2018015022A (es) | 2019-08-14 |
| EP3464350A1 (fr) | 2019-04-10 |
| WO2017211827A1 (fr) | 2017-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45149A (fr) | Méthodes de traitement de la maladie d'alzheimer | |
| MA49402A (fr) | Polynucléotides aadc pour le traitement de la maladie de parkinson | |
| MA41115A (fr) | Procédé de traitement de la maladie d'alzheimer | |
| MA45192A (fr) | Traitement d'association | |
| MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
| MA41028A (fr) | Méthodes et formulations pour le traitement de pathologies oculaires vasculaires | |
| ZA201605341B (en) | Methods of treating alzheimer's disease | |
| SG11201606490YA (en) | Methods of treating alzheimer's disease | |
| MA46353A (fr) | Méthodes de traitement de l'infertilité féminine | |
| MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| MA53329A (fr) | Méthodes de traitement de l'épilepsie | |
| DK3347002T3 (da) | Behandling af alzheimers sygdom i en bestemt patientpopulation | |
| DK3463351T3 (da) | Behandling til parkinsons sygdom | |
| MA45997A (fr) | Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d | |
| MA47395A (fr) | Méthode pour le traitement d'une maladie neurologique | |
| MA51678A (fr) | Méthodes de traitement de l'amyotrophie musculaire | |
| MA54792A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| MA47595A (fr) | Méthodes de traitement d'affections neurodégénératives | |
| FR3044227B1 (fr) | Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires | |
| MA43755A (fr) | Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte | |
| MA46967A (fr) | Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques | |
| MA46970A (fr) | Procédés de traitement de la maladie polykystique des reins | |
| MA48625A (fr) | Composés et méthodes de traitement de la douleur viscérale | |
| MA45258A (fr) | Dérivés de la thailanstatine a, méthodes de traitement et méthodes de synthèse de ceux-ci | |
| MA53602A (fr) | Méthodes de traitement du psoriasis |